Can the pharmaceutical industry reduce attrition rates?


The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Success rates from first-in-man to registration.
Figure 2: Success rate by phase of development and by therapeutic area.
Figure 3: Reasons for attrition (1991–2000).


  1. 1

    Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).

  2. 2

    Franz, S. 2003 approvals: a year of innovation and upward trends. Nature Rev. Drug Discov. 3, 103–105 (2004).

  3. 3

    Accenture Consulting. High performance drug discovery: an operating model for a new era. Accenture (2001).

  4. 4

    DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

  5. 5

    Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).

  6. 6

    Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nature Rev. Drug Discov. 2, 609–610 (2003).

  7. 7

    Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).

  8. 8

    Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).

  9. 9

    Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001).

  10. 10

    Gowen, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654–1663 (1999).

  11. 11

    Lazner, F., Gowen, M. & Kola, I. An animal model for pycnodysostosis: the role of cathepsin K in bone remodeling. Mol. Med. Today 5, 413–414 (1999).

  12. 12

    Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571–572 (2002).

Download references


We wish to acknowledge Datamonitor for the assembly of data (Pharmaceutical R&D Benchmarking Forum) used in this study.

Author information

Correspondence to Ismail Kola Ph.D. (Med).

Ethics declarations

Competing interests

I.K. is an employee of Merck & Co., Inc., and has financial interests in Merck, Pfizer Inc. and Schering-Plough Corp. J.L. is an employee of Schering-Plough Corp. and has financial interests in Schering-Plough and Pfizer Inc.

Related links

Related links



Rights and permissions

Reprints and Permissions

About this article

Further reading